Talengen International Limited
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Dec 2036
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Sep 26, 2027The maintenance fee for Method for regulating and controlling GLP-1/GLP-1R and drug (US 11,938,172) comes due Sep 26, 2027. Unpaid by Mar 27, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 24, 2026
- Sep 15 US 12,734,222 Method and Medicine for Treating Huntington's Disease
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,864,257 | Method for prevention or treatment of acute and chronic thrombosis In force · USPTO record | In force | USPTO record | |
| US 10,709,771 | Method for preventing or treating diabetic retinopathy In force · USPTO record | In force | USPTO record | |
| US 11,090,372 | Method of treating diabetic nephropathy comprising administering plasminogen In force · USPTO record | In force | USPTO record | |
| US 10,874,721 | Method for preventing and treating cervical erosion In force · USPTO record | In force | USPTO record | |
| US 11,007,253 | Method for preventing or treating radiation and chemical damage In force · USPTO record | In force | USPTO record | |
| US 11,129,880 | Method for Promoting Insulin Secretion In force · Medium confidence | In force | Medium confidence | |
| US 11,311,607 | Method for Making Glucagon and Insulin Restore Normal Balance In force · Medium confidence | In force | Medium confidence | |
| US 11,071,772 | Method for preventing and treating tissue and organ fibrosis In force · USPTO record | In force | USPTO record | |
| US 11,154,595 | Method for preventing and treating pulmonary fibrosis In force · USPTO record | In force | USPTO record | |
| US 11,219,669 | Method for preventing and treating liver fibrosis In force · USPTO record | In force | USPTO record |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
7 pending · 3 abandoned · 11 no status recorded